CA3110218A1 - Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma - Google Patents

Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma Download PDF

Info

Publication number
CA3110218A1
CA3110218A1 CA3110218A CA3110218A CA3110218A1 CA 3110218 A1 CA3110218 A1 CA 3110218A1 CA 3110218 A CA3110218 A CA 3110218A CA 3110218 A CA3110218 A CA 3110218A CA 3110218 A1 CA3110218 A1 CA 3110218A1
Authority
CA
Canada
Prior art keywords
patient
gaboxadol
hours
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3110218A
Other languages
English (en)
French (fr)
Inventor
Matthew During
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CA3110218A1 publication Critical patent/CA3110218A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3110218A 2018-08-22 2019-08-22 Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma Pending CA3110218A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721013P 2018-08-22 2018-08-22
US62/721,013 2018-08-22
PCT/US2019/047673 WO2020041574A1 (en) 2018-08-22 2019-08-22 Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma

Publications (1)

Publication Number Publication Date
CA3110218A1 true CA3110218A1 (en) 2020-02-27

Family

ID=69591079

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3110218A Pending CA3110218A1 (en) 2018-08-22 2019-08-22 Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma

Country Status (10)

Country Link
US (1) US20210177805A1 (enExample)
EP (1) EP3823619A4 (enExample)
JP (1) JP2021535106A (enExample)
KR (1) KR20210049855A (enExample)
CN (1) CN112888437A (enExample)
AU (1) AU2019326539A1 (enExample)
CA (1) CA3110218A1 (enExample)
IL (1) IL280859A (enExample)
MX (1) MX2021002113A (enExample)
WO (1) WO2020041574A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CN115551514A (zh) * 2020-03-25 2022-12-30 萨奇治疗股份有限公司 用于治疗呼吸系统病症的药物的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
AU4307800A (en) * 1999-04-30 2000-11-17 Merab Lomia New indication for use of antiepileptic agents and medicines
EP1863808A1 (en) * 2005-03-18 2007-12-12 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法

Also Published As

Publication number Publication date
EP3823619A4 (en) 2021-11-17
IL280859A (en) 2021-04-29
WO2020041574A1 (en) 2020-02-27
EP3823619A1 (en) 2021-05-26
JP2021535106A (ja) 2021-12-16
US20210177805A1 (en) 2021-06-17
AU2019326539A1 (en) 2021-03-11
KR20210049855A (ko) 2021-05-06
MX2021002113A (es) 2021-06-23
CN112888437A (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
US20200140371A1 (en) S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same
JP6353577B2 (ja) 組み合わせ組成物
CN111971035A (zh) 生酮饮食相容的芬氟拉明制剂
BR112021009365A2 (pt) formulação de glicocorticoide estável
Gracious et al. Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series
CA2735834C (en) Composition comprising ibuprofen and paracetamol to treat pain caused by osteoarthritis and rheumatoid arthritis
US20210177805A1 (en) Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
EP2338495A1 (en) Iron bis-glycinate chelate for use in the oral treatment of anemia in patients with celiac disease
Richardson et al. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents
Shakerdi et al. Inborn Errors of Amino Acid Metabolism Revisited: Clinical Implications and Insights into Current Therapies
CN119212693A (zh) 用于治疗肌萎缩性侧索硬化的牛磺酸二醇和苯丁酸钠的组合
US11090293B2 (en) Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
KR20210087952A (ko) 운동 장애들을 치료하기 위한 가복사돌, 가낙솔론 및 알로프레그나놀론의 사용
CN105193712B (zh) 盐酸氨溴索注射液和制法
US20230285369A1 (en) Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
EA051220B1 (ru) Стабильный состав глюкокортикоидов
WO2025137348A1 (en) Cyclobenzaprine hcl for use in treating fibromyalgia with early onset response and favorable tolerability and side effect profile
Buchman Bile Acid Sequestrants
US20240285564A1 (en) Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid for gastrointestinal tract disorders and as an immunomodulatory agent
CN115607556A (zh) 预防治疗哮喘或慢阻肺或过敏性疾病等的药物
JP2022540854A (ja) 疼痛を緩和するためのイブプロフェン及びトラマドールの組合せ